IP Verse

Method For Labeling A Prostate-Specific Membrane Antigen Ligand With A Radioactive Isotope

Patent No. EP3763394 (titled "Method For Labeling A Prostate-Specific Membrane Antigen Ligand With A Radioactive Isotope") was filed by Isotopia Molecular Imaging on Mar 2, 2016. The application was issued on Nov 8, 2023.

Patent Summary

Radiolabeling prostate-specific membrane antigen (PSMA) ligands with suitable radioactive isotopes, such as 68Ga, 90Y, and 177Lu, under mild reaction conditions (e.g., room temperature) and for short periods of time (e.g., 3 to 30 minutes), while still obtaining quantitative radiochemical yields, wherein said radiolabeled PSMA is suitable for the diagnosis or therapy of prostate cancer.

Patent Family

Patent Family

Patent Oppositions (2)

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentative
JAMES POOLEAug 1, 2024CARPMAELS & RANSFORD
TELIX INNOVATIONSAug 1, 2024DE CLERCQ & PARTNERS

Dossier Documents

The dossier documents provide a comprehensive record of the patent's prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent's legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents

EP3763394

ISOTOPIA MOLECULAR IMAGING
Application Number
EP20193861A
Filing Date
Mar 2, 2016
Status
Granted And Under Opposition
Oct 6, 2023
Publication Date
Nov 8, 2023
External Links
Slate, Register , Google Patents